Biogen would like to commend our collaboration partner, Eisai, on today's U.S. Food and Drug Administration approval of LEQEMBITM via the Accelerated Approval pathway. Additional details can be found in a news release announcing the approval. An additional news release from Eisai on patient safety is available on Eisai’s website.
A separate news release from Eisai on LEQEMBI pricing is also available via their website. Eisai is solely responsible for setting LEQEMBI’s price.
Efforts focused on four areas: access and health equity, workforce and DE&I, community impact and the environment CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced publication of its 2023 Corporate Responsibility Report detailing progress on the company’s
CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE™ to the reference product ROACTEMRA ® CAMBRIDGE, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the Committee for Medicinal Products for Human